AFib CDA
Detailed App Info:
Application Description
The availability of new antithrombotic agents, each with a unique efficacy and bleeding profile, has introduced a considerable amount of clinical uncertainty with physicians. We have developed a clinical decision aid that assists clinicians in determining an optimal antithrombotic regime for the prevention of stroke in patients who are newly diagnosed with non-valvular atrial fibrillation.
This iPad Application allows physicians to accurately and efficiently estimate an individual patient’s baseline annual absolute risk of stroke and bleeding using the CHA2DS2-VASc and HAS-BLED scoring systems.
The Clinical Decision Aid then identifies the antithrombotic agent that is associated with the lowest Net Risk to the patient, and recommends an optimal antithrombotic regime for the prevention of stroke based upon the patient’s particular CHA2DS2VASc and HAS-BLED Scores.
This iPad Application allows physicians to accurately and efficiently estimate an individual patient’s baseline annual absolute risk of stroke and bleeding using the CHA2DS2-VASc and HAS-BLED scoring systems.
The Clinical Decision Aid then identifies the antithrombotic agent that is associated with the lowest Net Risk to the patient, and recommends an optimal antithrombotic regime for the prevention of stroke based upon the patient’s particular CHA2DS2VASc and HAS-BLED Scores.
Requirements
Your mobile device must have at least 7.64 MB of space to download and install AFib CDA app. AFib CDA was updated to a new version. Purchase this version for $4.99
If you have any problems with installation or in-app purchase, found bugs, questions, comments about this application, you can visit the official website of Clinical Support Systems Clinical Support Systems, Inc. at http://support.clinicalsupportsystems.com.
Copyright © 2012 Clinical Support Systems, Inc.
